Quick Answer
A UC San Diego study published June 11, 2026 in Nature Communications found semaglutide slowed biological aging by 9% on the DunedinPACE epigenetic clock — the first randomised controlled evidence that a GLP-1 drug can slow aging processes at the cellular level.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
A landmark study published on June 11, 2026 in the journal Nature Communications has found that semaglutide — the active ingredient in Ozempic and Wegovy — slowed biological aging by 9% as measured by an established epigenetic clock. Conducted by researchers at the University of California, San Diego, this is the first randomised, double-blind, placebo-controlled clinical evidence that a GLP-1 drug can slow the biological processes associated with aging at the cellular level. While the study is not a final word, it opens a new chapter in what GLP-1 drugs may ultimately offer — including for millions of Indian patients who take them primarily for diabetes or weight loss.
What the Study Found
Researchers at UC San Diego analysed data from a previously published clinical trial involving 108 adults with HIV-associated lipohypertrophy, a condition involving excess abdominal fat. Roughly half received weekly semaglutide injections and the other half received placebo injections over 32 weeks. To track aging, the team used a set of biological tools called epigenetic clocks. These clocks measure chemical marks on DNA — known as methylation — that reflect how cells are aging across different organ systems including the brain, heart, kidney, liver, and blood.
The findings were striking. Compared to the placebo group, participants who received semaglutide showed a broad pattern of slower biological aging across multiple epigenetic clocks. The DunedinPACE clock — which measures the pace of biological aging — showed a 9% reduction in aging rate among semaglutide users. The PCGrimAge clock, which predicts risk of all-cause mortality and age-related disease, also showed significantly slower aging in the semaglutide group.
A related pilot study published in npj Aging added supporting evidence. In that study, semaglutide reduced the rate of biological aging in 42% of participants, slowed mortality-associated aging in 34%, and increased telomere length — repetitive DNA sequences that protect genetic material and are associated with longevity — in nearly 49% of participants. Patients who gained telomere length also showed better physical function, walking faster after treatment.
What Are Epigenetic Clocks and Why Do They Matter?
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Biological age and chronological age are not the same thing. Two people can be 55 years old by the calendar but have very different biological ages depending on how their DNA has accumulated aging-related chemical marks over time. Epigenetic clocks measure these marks and produce an estimate of how old the body is functioning at a cellular level — which often predicts health outcomes better than a patient's birth year.
Slowing the pace of biological aging even by a small amount could translate into meaningful reductions in the risk of heart disease, kidney disease, liver disease, neurological decline, and cancer — all diseases that are associated with accelerated biological aging. The UC San Diego team believes semaglutide may work on aging through several pathways: by reducing chronic inflammation, by shrinking visceral fat that drives inflammatory and metabolic stress, and by potentially reprogramming certain cells in organs in ways that are still being investigated.
Why This Matters for Indian Patients
India has one of the fastest-aging populations in the world, and Indian bodies tend to show the metabolic consequences of aging earlier than Western populations due to genetic and lifestyle factors. Indians develop diabetes, fatty liver disease, and cardiovascular complications at lower BMIs and younger ages compared to most Western patients. The same inflammatory and metabolic pathways that drive accelerated aging are already more active in many Indian patients by the time they reach middle age.
For Indian patients who already take semaglutide for type 2 diabetes or obesity, this research suggests the drug may be doing something additional — quietly slowing the cellular mechanisms that drive age-related disease, beyond what blood sugar and weight data alone can show. For patients who qualify for GLP-1 therapy but have been hesitant to start, the anti-aging signal adds yet another dimension to the decision.
Important Caveats to Understand
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The researchers themselves are careful about how these findings should be interpreted. The study was conducted in people with HIV, who experience accelerated aging for reasons specific to that condition. Whether the anti-aging effects observed apply equally to the general population has not yet been confirmed in a separate trial. The sample size of 108 participants is relatively small for clinical conclusions. Larger clinical trials — in people without HIV, across a range of ages and metabolic profiles — are needed before semaglutide can be described as an anti-aging treatment in the clinical sense.
Lead researcher Michael Corley, PhD, associate professor at UC San Diego School of Medicine, was explicit: we are not saying that semaglutide reverses aging or makes people younger. What we are seeing is a signal that it may slow some of the biological processes associated with aging. That distinction matters — this is emerging science, not established practice.
What Indian Patients Should Do With This Information
If you have type 2 diabetes, obesity, or metabolic syndrome, you already have strong medical reasons to consider GLP-1 therapy. The anti-aging research is a meaningful additional signal, not a reason to start the drug without medical guidance. GLP-1 medications require proper assessment for eligibility, careful dose titration, and monitoring. They are not suitable for everyone, and they should always be started under a doctor's supervision.
Access has improved dramatically. Generic semaglutide is now available in India from approved manufacturers at approximately Rs 3,500 to Rs 6,000 per month — a fraction of the cost of branded Ozempic. A GLP-1 specialist can assess your eligibility, select the right formulation and dose, and monitor your progress safely.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. University of California — https://www.universityofcalifornia.edu/news/new-study-shows-popular-glp-1-weight-loss-drug-may-slow-biological-aging 2. Nature Communications — https://www.nature.com/articles/s41467-026-72861-3 3. Stanford Medicine — https://med.stanford.edu/news/all-news/2026/06/muscle-glp-1.html
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.